CAR-T cell therapy for advanced bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 1/2 trial tests CAR-T therapy—a treatment where immune cells are changed to better attack cancer—for bladder cancer that has spread or grown locally. It may help shrink tumors and control the disease by boosting a patient’s immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer (or related urinary tract cancer) that is locally advanced or metastatic, confirmed by pathology (tissue/urine tests)
- You can provide tumor samples for the study to analyze
- Your blood counts and major organs (like liver/kidney) are healthy enough for treatment
- Your day-to-day function is good (ECOG 0–1) and you’re expected to live at least 12 weeks
- Your scans show measurable cancer that can be tracked (per RECIST 1.1)
- You do not have certain recent treatments or health problems that would make CAR-T unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.